- Juno Therapeutics, Inc. stock price today and history
Please, Signup (Login) to subscribe or trade (demo)
Juno Therapeutics, Inc. stock price
Juno Therapeutics, Inc. latest news:
Celgene's stock gains after profit beats expectations
Shares of Celgene Corp. rallied 1.7% in premarket trade Thursday, after the biopharmaceutical company reported a fourth-quarter profit that rose above expectations. The company swung to a net loss of $81 million, or 10 cents a share, in the quarter to Dec. 31, from a profit of $429 million, or 53 cents a share, in the same period a year ago. Excluding non-recurring items, such as the one-time effect of the tax-reform legislation, adjusted earnings per share rose to $2.00 from $1.61, beating the FactSet consensus of $1.97. Revenue increased to $3.48 billion from $2.98 billion, in line with the FactSet consensus of $3.47 billion, as 21% growth in sales of its blockbuster cancer treatment Revlimid to $2.2 billion matched expectations. For 2018, the company expects revenue of $14.4 billion to $14.8 billion, compared with the FactSet consensus of $14.8 billion, while the adjusted EPS outlook of $8.70 to $8.90 was above expectations of $8.63. Earlier this week, Celgene announced a deal to buy Juno Therapeutics Inc. for about $9 billion. The stock has tumbled 13.8% over the past three months, while the iShares Nasdaq Biotechnology ETF has climbed 8.2% and the S&P 500 has gained 11%.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
Celgene to buy Juno for $9 billion
Celgene announced a $9 billion cash buyout of Juno Therapeutics as it moves to cement its position as a key player in a new range of cancer therapies. Aleksandra Michalska reports.
Video provided by Reuters
Bioverativ, Juno and Halliburton rise; Sanmina-SCI tumbles
Bioverativ, Juno Therapeutics and Halliburton advance while Sanmina-SCI tumbles
U.S. stocks open slightly lower in first trading day of government shutdown
U.S. stocks fell modestly at the open on Monday, as investors found few reasons to keep pushing shares higher following a push to repeated records, and as the government shutdown provided another element of uncertainty to markets. The Dow Jones Industrial Average fell 72 points, or 0.2%, to 26,011. The S&P 500 declined 1 point to 2,809, a drop of less than 0.1%. The Nasdaq Composite Index was unchanged at 7,336. Both the S&P and the Nasdaq are coming off closing records, while the Dow is close to its own peak. While government shutdowns have historically not been big selling catalysts, uncertainty over when the government would reopened appeared to dampen buying enthusiasm. The Senate was expected to hold a procedural vote at noon Eastern Time on a measure that would keep the government funded through Feb. 8, but it wasn't clear if it would have enough support to advance. In company news, Juno Therapeutics Inc. jumped 27% after Celgene Corp. agreed to buy the company for $9 billion. Bioverativ Inc. soared 63% after Sanofi SA said it would buy it for $12 billion.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
Deals of the day-Mergers and acquisitions
The following bids, mergers, acquisitions. ** Celgene Corp (CELG) said it agreed to buy rest of Juno Therapeutics Inc (JUNO) for about $9 billion in cash to gain access to Juno's pipeline of CAR-T cancer drugs.
Juno and Boeing climb while Goldman Sachs and GE drop
Stocks that moved substantially or traded heavily Wednesday: Juno Therapeutics Inc., up $23.65 to $69.25 The Wall Street Journal reported that biotech drugmaker Celgene may buy the cancer therapy company.
Celgene in talks to buy Juno Therapeutics - WSJ
Celgene Corp(CELG) is in talks to buy Juno Therapeutics Inc (JUNO), the Wall Street Journal reported, citing sources familiar with the matter. Shares of Juno, which has a market value of $5.57 billion, were up 36 percent at $62.50 in extended trading on Tuesday.
Celgene in talks to buy Juno Therapeutics: report
Celgene Corp. is in talks to buy Juno Therapeutics Inc. , according to a report on The Wall Street Journal Tuesday that cited unnamed sources. Juno is a biotech company developing cancer treatments. Juno stock soared more than 30% in late trading Tuesday and ended the regular trading day down 6.5%. Celgene shares rose 1% and closed the regular session down 1.1%. Celgene earlier this month released preliminary fourth-quarter and full-year 2017 results and provided a downbeat outlook for 2018. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
K2M Group Holdings, Inc.KTWO
Kaiser Aluminum CorporationKALU
KaloBios Pharmaceuticals, Inc.KBIO
Kandi Technologies Group, Inc.KNDI
Kansas City Life Insurance CompanyKCLI
Karyopharm Therapeutics Inc.KPTI
KBS Fashion Group LimitedKBSF
KCAP Financial, Inc.KCAP